From the regulatory network analysis, the NR5A1 regulon activity was found to be related to worse outcomes in OS and progression-free interval both in the TCGA-ACC cohort, as well as in the ENSAT cohort. Here, NR5A1 is linked to adrenal cortex carcinoma.